Given these challenges, recent advances in AD research emphasize the need for multi-target drug design strategies that simultaneously address Aβ accumulation, tau pathology, oxidative stress, and neuroinflammation [23,24,25,26,27]. The gene discussed is MAPT; the disease is Alzheimer disease.